Korro Bio Inc.

Biotechnology: Pharmaceutical Preparations company

2019 📍 United States NASDAQ KRRO Pharmaceuticals & Healthcare

Search companies

Key Metrics of Korro Bio Inc.

Revenue₹57.4 Cr▲ 195.5% YoYFY 2025-26

EBITDA−₹1,057 Cr▼ 39.7% YoY

Net profit−₹1,054 Cr▼ 47.3% YoY

Net worth₹462 Cr▼ 66.3% YoY

Market cap$204MKRRO · $13.86

Competitors10identified

About Korro Bio Inc.

Sectors

Pharmaceuticals & HealthcareBiotechnology & Vaccines

Company details

Founded: 2019
Listed: Nasdaq: KRRO (since 2019)

Operational Areas of Korro Bio Inc.

Pharmaceuticals & Healthcare›Biotechnology & Vaccines

Company summary

Legal nameKorro Bio Inc.

TickerKRRO

ExchangeNasdaq

CountryUnited States

SEC CIK0001703647

Listed since2019

IndustryBiotechnology: Pharmaceutical Preparations

SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines

Website—

US market & SEC filings

KRRO · Nasdaq · SEC CIK 0001703647

Last price · 30 Oct 2026 $13.86 +4.21%

Market cap$204M

P/E—On FY 2023 diluted EPS

Volume269,327

SectorHealth CareBiotechnology: Pharmaceutical Preparations

Country · IPOUnited StatesListed 2019

KRRO share price

Premium

Annual results (SEC EDGAR)

Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Vendor checks & payment capacity

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Consolidated accounts · FY 2025-26

Indicative long-term—

Indicative short-term—

Score—

LiquidityAdequate

DirectionStable

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

Default	No default on record
Issuer cooperation	Cooperating
Credit enhancement	None – standalone rating
Information on file	33% · missing: Debt obligations and repayment schedule, Capex / investment plans, Lender details, Auditor details, Shareholding pattern, Recent rating review (last 15 months)

Indicative assessment from public data using the published methodology factors; not a credit rating.

Registered office and contact

Registered office—

GSTIN—

Email—

Website—

Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Competitors of Korro Bio Inc.

Competitors10identified

Countries1most in United States

Top competitors by location

Company	Description	Domain	Founded	Location
Vertex Pharmaceuticals	Part of Vertex Pharmaceuticals.	vrtx.com	1991	United States
Moderna	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	modernatx.com	2018	United States
Becton Dickinson	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	bd.com	—	United States
Illumina	Part of Illumina.	illumina.com	2000	United States
Guardant Health	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	guardanthealth.com	2018	United States
Revvity Inc.	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	revvity.com	—	United States
Exelixis	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	exelixis.com	2000	United States
Neurocrine Biosciences	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	neurocrine.com	1996	United States
Twist Bioscience	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	twistbioscience.com	2018	United States
10X Genomics	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	10xgenomics.com	2019	United States

Similar companies

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Business activities and related parties

Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.

Filings

No filings on record yet.